An Observational Registry of Abatacept in Patients With Juvenile Idiopathic Arthritis
Phase of Trial: Phase IV
Latest Information Update: 04 May 2018
At a glance
- Drugs Abatacept (Primary)
- Indications Juvenile rheumatoid arthritis
- Focus Adverse reactions
- Sponsors Bristol-Myers Squibb
- 08 Nov 2017 Results (n= 354) presented at the 81st American College of Rheumatology and the 52nd Association of Rheumatology Health Professionals Annual Scientific Meeting
- 11 Nov 2015 Interim results (n = 146) presented at the 79th American College of Rheumatology and the 50th Annual Meeting of the Association of Rheumatology and Health Professionals.
- 22 Feb 2015 Planned End Date changed from 1 Jun 2029 to 1 Dec 2029 as reported by ClinicalTrials.gov record.